Skip to main content

Advertisement

SpringerLink
Log in

Initial experience of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with heart failure and renal anemia

  • Short Communication
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors might improve renal anemia maintaining fewer cardiovascular complications. However, its safety and efficacy, as well as its impact on inflammatory biomarkers, in heart failure patients remain unknown. We initiated HIF-PH inhibitors in 13 patients with chronic heart failure and renal anemia (median age 77 years, median estimated glomerular filtration rate 24.9 mL/min/1.73m2) between September 2021 and February 2022. There were no drug-related complications, except for a patient who had a headache and hot flash, resulting in discontinuation of HIF-PH inhibitor at 3 months. Among 10 patients who continued HIF-PH inhibitors for over 3 months, hemoglobin levels increased significantly (median from 9.6 g/dL to 10.7 g/dL, p = 0.004) and hepcidin-25 levels tended to decrease (median from 11.5 ng/mL to 3.0 ng/mL, p = 0.294) at 3-month follow-up. In conclusion, HIF-PH inhibitors might be safe and effective for the treatment of renal anemia in patients with chronic heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Anand IS, Gupta P (2018) Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation 138(1):80–98

    Article  CAS  Google Scholar 

  2. Anand IS (2008) Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol 52(7):501–511

    Article  Google Scholar 

  3. van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, van Veldhuisen DJ (2004) Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44(1):63–67

    Article  Google Scholar 

  4. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O’Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ (2013) Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368(13):1210–1219

    Article  CAS  Google Scholar 

  5. Gupta N, Wish JB (2017) Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis 69(6):815–826

    Article  CAS  Google Scholar 

  6. Eleuteri E, Di Stefano A, Giordano A, Corra U, Tarro Genta F, Gnemmi I, Giannuzzi P (2016) Prognostic value of angiopoietin-2 in patients with chronic heart failure. Int J Cardiol 212:364–368

    Article  Google Scholar 

  7. Poss J, Ukena C, Kindermann I, Ehrlich P, Fuernau G, Ewen S, Mahfoud F, Kriechbaum S, Bohm M, Link A (2015) Angiopoietin-2 and outcome in patients with acute decompensated heart failure. Clin Res Cardiol 104(5):380–387

    Article  Google Scholar 

  8. Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, Szczech L (2013) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis 62(5):849–859

    Article  Google Scholar 

  9. Ganz T (2011) Hepcidin and iron regulation, 10 years later. Blood 117(17):4425–4433

    Article  CAS  Google Scholar 

  10. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113(9):1271–1276

    Article  CAS  Google Scholar 

  11. Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, Shah VO, Balakrishnan VS, Guzman NJ, Girndt M, Periera BG, Feldman HI, Kusek JW, Joffe MM, Raj DS (2012) Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 7(12):1938–1946

    Article  CAS  Google Scholar 

  12. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103(16):2055–2059

    Article  CAS  Google Scholar 

  13. von Haehling S, Anker SD (2011) Cardio-renal anemia syndrome. Contrib Nephrol 171:266–273

    Article  Google Scholar 

  14. Kurata Y, Tanaka T, Nangaku M (2020) Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease. Curr Opin Nephrol Hypertens 29(4):414–422

    Article  CAS  Google Scholar 

  15. Palazzuoli A, Silverberg DS, Iovine F, Calabrò A, Campagna MS, Gallotta M, Nuti R (2007) Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 154(4):645.e9–15

    Article  Google Scholar 

Download references

Acknowledgements

None.

Funding

None.

Author information

Authors and Affiliations

  1. Second Department of Internal Medicine, University of Toyama, 2630 Sugitani Toyama-shi, Toyama, 930-0194, Japan

    Makiko Nakamura, Teruhiko Imamura, Mitsuo Sobajima & Koichiro Kinugawa

Authors
  1. Makiko Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teruhiko Imamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mitsuo Sobajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Koichiro Kinugawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Teruhiko Imamura.

Ethics declarations

Conflict of interest

None.

Ethical standards

IRB information: Clinical Research Review Board, University of Toyama, IRB number R2015154.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakamura, M., Imamura, T., Sobajima, M. et al. Initial experience of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with heart failure and renal anemia. Heart Vessels 38, 284–290 (2023). https://doi.org/10.1007/s00380-022-02181-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-022-02181-1

Keywords

Search

Navigation